SWK Holdings Corporation (SWKH) reported a solid first quarter in 2024, with a 24% increase in Finance segment revenue, reaching $11.5 million. The company’s Enteris segment entered into an exclusive option and purchase agreement with a strategic partner, indicating growth potential. Despite facing a $6 million impairment in its loan book, SWK Holdings maintained profitability and continued to focus on financing life science product companies, particularly through first lien term loans and royalties. The company also repurchased shares, leading to an increase in book value per share. However, challenges were evident in the Enteris segment, where the company acknowledged poor execution and missed opportunities in securing additional licenses for its Peptelligence technology.
Key Takeaways
- SWK Holdings’ Finance segment revenue increased by 24% to $11.5 million.
- The company signed an exclusive option and purchase agreement with a strategic partner for its Enteris segment.
- Despite a $6 million impairment, SWK Holdings remains profitable.
- The company is actively seeking loan and royalty opportunities, focusing on small and mid-sized life science companies.
- Share repurchases contributed to an increase in book value per share.
- The Enteris segment faced challenges with Peptelligence technology licensing and has refocused on classic CDMO operations.
Company Outlook
- SWK Holdings is prioritizing investments in the life science finance market, targeting small and mid-sized companies.
- The company is pursuing growth through strategic partnerships and loan and royalty opportunities.
Bearish Highlights
- SWK Holdings admitted to poor execution with Enteris’ Peptelligence technology, leading to downsizing and missed licensing opportunities.
- Efforts to monetize the Enteris IP are ongoing, but the possibility for significant deals has diminished.
Bullish Highlights
- The company remains profitable and is experiencing growth in its Finance segment.
- SWK Holdings is optimistic about the potential for licensing opportunities, despite past challenges.
Misses
- The company recognized the missed potential in securing additional licenses for Peptelligence technology.
Q&A Highlights
- CEO Paul Shields discussed refocusing on classic CDMO operations and the unique dosing types for Phase 1 and Phase 2 evaluations.
- Shields acknowledged the superior efficacy of Peptelligence in delivering API but noted the difficulty in proving its value proposition to potential partners.
- The CEO expressed openness for further discussions, highlighting the company’s ongoing pursuit of strategic opportunities.
In conclusion, SWK Holdings has shown resilience in the face of setbacks in its Enteris segment and is looking to capitalize on its strengths in the life science finance market. The company’s strategic focus and recent financial performance indicate a commitment to growth and value creation for its shareholders.
InvestingPro Insights
SWK Holdings Corporation (SWKH) has demonstrated a strong financial posture, with key metrics indicating a robust balance sheet and potential for growth. The company’s market capitalization stands at a stable $219.52 million, reflecting investor confidence in its market position and business strategy. With a Price to Earnings (P/E) ratio of 15.76 for the last twelve months as of Q1 2024, SWK Holdings is valued by the market at a level that suggests investors are expecting earnings growth in line with the company’s historical performance.
An InvestingPro Tip highlights that SWK Holdings’ liquid assets currently exceed its short-term obligations, which is a positive sign of the company’s liquidity and ability to meet its immediate financial commitments. This is particularly relevant for investors considering the company’s recent share repurchase initiative, as it demonstrates financial flexibility.
Another InvestingPro Tip indicates that analysts predict the company will be profitable this year, which aligns with the reported profitability over the last twelve months. This underscores the company’s consistent performance, despite the challenges faced in the Enteris segment.
Investors might also be interested to know that SWK Holdings does not pay a dividend. This decision may allow the company to reinvest earnings back into the business, potentially funding growth opportunities and further development of its life science financing portfolio.
For those seeking a deeper dive into SWK Holdings’ financial health and future prospects, there are additional InvestingPro Tips available at Using coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking more expert insights and detailed analysis.
Full transcript – Swk Hldgs Corp (SWKH) Q1 2024:
Operator: Good morning, everyone, and welcome to the SWK Holdings First Quarter 2024 Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Jason Rando. Sir, the floor is yours.
Jason Rando: Good morning, everyone, and thank you for joining SWK Holdings first quarter 2024 financial and corporate results call. Yesterday evening, SWK Holdings issued a press release detailing its financial results for the three months ended March 31, 2024. The press release can be found in the Investor Relations section of swkhold.com under News Releases. Before beginning today’s call, I would like to make the following statement regarding forward-looking statements. Today, we’ll be making certain forward-looking statements about future expectations, plans, events and circumstances including statements about our strategy, future operations, and our expectations regarding our capital allocation and cash resources. These statements are based on our current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in the Risk Factors section of SWK Holdings 10-K filed with the SEC and other filings we make with the SEC from time to time. SWK Holdings disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise. Joining me from SWK Holdings on today’s call is Jody Staggs, President and CEO, who will provide an update on SWK’s first quarter 2024 corporate and financial results. Jody, go ahead.
Jody Staggs: Thank you, Jason, and thanks, everyone, for joining our first quarter conference call. SWK’s first quarter of 2024 results were highlighted by a 24% growth in Finance segment revenue to a near all-time high of $11.5 million, while our Enteris segment signed an exclusive option and purchase agreement with a strategic partner that reduces the operating burn and may lead to the acquisition of certain CDMO-related tangible assets. SWK’s core business is financing commercial stage life science product companies do first lien term loans and royalties with a focus on $5 million to $25 million investments. We have concentrated on this niche for over a decade and have developed an extensive network and strong experience, spanning the three core functions of a direct credit firm, origination, underwriting and portfolio management. These capabilities were evidenced during the first quarter as our Finance segment generated a 10.3% year-over-year increase in gross finance receivables portfolio to $274.5 million, coupled with a 14.2% effective yield and 16.3% realized yield. These achievements led to a 24% year-over-year increase in segment revenue to $11.5 million. This performance enabled our Finance segment to remain profitable in the quarter, generating $1 million of GAAP net income and $2.7 million of adjusted non-GAAP net income despite being negatively impacted by a $6 million impairment in our loan book. We are constructive on the life science finance market and are actively pursuing multiple loan and royalty opportunities while remaining cognizant of increased competition in certain pockets of the life science finance market. While many of our competitors have grown to a size where they must focus on large sponsor-backed opportunities, we believe SWK’s focus on the less competitive sub-$25 million market remains a competitive differentiator. During the first quarter, our Enteris division signed an exclusive option and asset purchase agreement with a strategic partner, granting the partner a two-year exclusive option to purchase certain Enteris tangible assets in exchange for option fees and guaranteed revenue payments. In April, we received the first low single-digit million-dollar option fee. The guaranteed revenue payments are chewed up every six months, and we expect to receive the first guaranteed revenue payment in the third quarter. Our first quarter financial results did not include any revenue from either the option fee or guaranteed revenue payments. As we highlighted on our fourth quarter call, the agreement immediately reduces the cash burn on Enteris, and we believe the business will be breakeven or better over the duration of the agreement. The agreement also provides our colleagues at Enteris opportunities to work with our partner to increase the project pipeline and generate new business, while allowing SWK to prioritize our specialty finance business focused on investing in small and midsized commercial stage life science companies. Turning to our share repurchase program. We bought back 58,298 shares at a total cost of $1 million during the quarter. Since quarter close, we repurchased an additional 19,000 shares for a total cost of $300,000. At March 31 — March 30, 2024, our book value per share was $22.46, a 5% increase compared to $21.39 in the year ago period. Non-GAAP tangible financing book value per share totaled $19.69, an approximately 17% increase from the year ago period. For the first quarter of 2024, the realized yield of the finance receivables portfolio was 16.3% versus 15% — approximately 15% for the same period in the prior year. In summary, first quarter of 2024 was largely as expected with the exception of the $6 million loan impairment. For the remainder of 2024, we will prioritize selectively closing commercial stage life science loan and royalty transactions that fit our underwriting criteria, working with our nonaccrual borrower partners to realize positive outcomes, exploring paths for additional capital and returning capital to shareholders via our buyback program. With that, let’s open the call to questions.
Operator: [Operator Instructions] Your first question is coming from Mark Argentino from Lake Street.
Mark Argento: Jody, just a couple of quick ones. One, could you just touch on the impairment? What was it? And then two, what’s your kind of lending base or capacity right now?
Jody Staggs: Yes. Thanks, Mark. Yes. So the impairment was to our Trio loan, which was carried at $9.6 million at [12 30]. Yes, the situation remains in work out, there is a restructuring ongoing. So we remain positive towards the potential outcome here, but it’s — I think the restructuring happened a little quicker than we would have thought. It was a little bit more rush than we would have thought. And as it goes — the business goes through that, there’s likely to be some disruptions. Given that — given our structure under the restructuring, we felt this impairment was positive — excuse me, it was not positive — was appropriate. We’re — as we get a little further out from it, we’ll do a full write-up and analysis of what happened here. It was a U.K. borrower. We’ve only done a few of those. I think we need to do a deep dive and understand if that played a role here. There’s some other dynamics that, I think, in my mind, happened, and we’ll definitely use this as a learning experience. In terms of our lending capacity, we — the revolver — as we stand today, the revolver is undrawn. I think we’ve got a few million dollars of cash. So we have plenty of capacity, let’s say, $50 million to — $50 million. We’ve got some undrawn commitments and things like that. But we’re in the $45 million to $50 million of capacity. The — I was talking to the team yesterday about what we’ve done year-to-date, and I think we would have liked to have closed some deals. We actually have submitted about $200 million of proposals year-to-date, which is up year-over-year, and we have about $60 million of proposals outstanding. So I think we’re doing — we’re running our playbook. We’re out there originating — we’re out there finding potential partners. We’re out there submitting proposals. The market has turned a bit — a bit more competitive, and that’s both the sort of general dynamic of a new player or two in the market, plus with equity markets moving higher, that’s an alternative for some of these companies. So I don’t think we’re going to be doing anything drastically different, but I’ve sort of challenged the team to think through our process, our proposals, other things we should be doing differently, are we out there hustling every day making sure that we’re staying in front of these companies and putting the best proposal forward to get some closings.
Mark Argento: That’s helpful. And then has any of your portfolio companies accessed the equity markets in terms of raising additional equity capital? Or how do you guys do broader capital markets right now?
Jody Staggs: Yes. Yes. So we do have some private companies that have raised capital recently, one public company as well, and I suspect others are evaluating that, given it’s — those are open. So it’s a double-edged sword. It’s great for our portfolio companies, more equity. We refinanced cash [boarding] life science company. So it’s important that they have some ability to raise equity, particularly when things are good. It does make originating new loans, I would say, modestly more challenging.
Operator: [Operator Instructions] Your next question is coming from William Koch.
Unidentified Analyst: This is Bill Koch calling. I’m a shareholder. I’m not a financial person. In fact, I’m — in fact, I’m a criminal defense lawyer. I don’t — all the financial numbers are, I think, great with this company. The only reason why I’m a shareholder, though is — and this is my question — questions, actually, I have a lot of questions. The only reason why I’m a shareholder is because SWK owns Enteris, and I owned Unigene stock 20, 25 years ago. I’d like — so it’s almost like I’d like to have like a lot of questions, and I couldn’t really — I mean, I know what they are, but I couldn’t really formulate them given the — given that I just found out last night that this conference call is going to be this morning. But going back to stuff that Unigene did, some of the — some of the situations they were in, like with Pfizer (NYSE:) and how they competed with Emisphere through the years, all the deals, the big deals they had that Unigene had and then Enteris had with sort of potentially never worked out, but potential blockbuster drugs. So I’m not sure if I could — should just start asking questions or if I could send you an e-mail.
Jody Staggs: Yes. Let me — let me maybe kind of frame it this way, and maybe it makes sense for us to get on a call too, because I can walk you through kind of what’s happened, SWK’s involvement and a lot of specifics around Unigene in the transition. So we purchased Enteris, it’s been over four years ago, might have been five years ago. And at the time, the thesis really was, hey, this is a cool technology. They’re helping peptide and certain small molecules go from IV to oral. There were some interesting things in the pipeline. And yes, we saw the Emisphere transaction and sort of their involvement with GLP-1s, and we thought, wow, this is pretty cool. Fast — and they had signed the license with Cara. So we felt like that validated technology, and we liked that a lot. Kind of fast forward, I would say the execution wasn’t great, and we certainly hold responsibility for that. I would say the window was kind of missed. So they’re still talking to folks about additional licenses. And we’ve come close a couple of times, but the window was sort of missed. There was probably a four- or five-year window when there was some opportunities to get some things done. And again, execution wasn’t great. So when the Board put me in as CEO, we looked at that business and said, “Hey, can we really add value doing what we’re doing now?” And if you look at our financials, it was a cash burning situation. So we were sending money for our finance business to Enteris, which none of us wanted to do. And we made the decision to really downsize that business. So we reduced the headcount. There’s a new CEO there named Paul Shields, and we really refocused that around kind of classic CDMO operations. So their focus right now on some sort of unique dosing types and helping companies evaluate those dosing types in Phase 1 and Phase 2. So, we still have Peptelligence. There are still some efforts to do some licenses there. As mentioned, we’re talking to people, and we’ve come close a couple of times, but unfortunately, I think the window for monetizing that IP is probably not — not all the way closed, but it’s not where it was five years ago.
Unidentified Analyst: Okay. Well, I guess that kind of — yes, because — I mean, [indiscernible] much time here, but — all Emisphere had was an oral delivery technology that I believe, [Unigene’s] was actually shown, I think, in those calcitonin studies years ago to be better than Emisphere’s technology in terms of delivering the API into the bloodstream and Emisphere was bought by Novo for over $1 billion. So that’s kind of why I thought like, wow, this — SWK has money and maybe they can move Enteris forward to some — some sort of huge big deals like that. But I guess what you’re saying is that’s not going to happen.
Jody Staggs: I would say it’s — we haven’t given up. There’s still some efforts there. But look, you’re exactly saying our thesis. That is exactly what we thought. We purchased it for, I think, $19 million. We got some of the Cara license. So your thesis is exactly what we thought. And at the time, I think we thought and — there was some work in the pipeline on GLP-1, and I don’t want to get too in the weeds here, but — so we saw all those same things about this — this could be a huge upside scenario. So again, I don’t think it was a crazy idea. Didn’t work out like we would have hoped. But yes, I think your points are well taken. And just I guess last comment I would say is, if you look at any of these dosing companies’ technologies, most of the large pharma biotechs, they have — some of them — they do have internal capabilities. And you’re right, like the Peptelligence technology is — from what we’ve seen from data from talking to partners, it’s the best out there in terms of getting certain API where it needs to go. However, is it — is that a differentiating enough factor to get someone to pay a royalty, that’s always a challenge. So if you can get 10% of the API where it needs to go versus 5%, that’s awesome. That’s great. Is it valuable enough for someone to pay a royalty or they say, “You know what, 5%, we can maybe up the milligram and still get the coverage we need?” So that’s what you’re always wrestling with there.
Unidentified Analyst: Okay. All right. I appreciate it.
Jody Staggs: Absolutely, yes. And feel free to call, I’m happy to chat on that, and we’d love to hear your views on sort of what happened there.
Operator: There are no further questions in the queue.
Jody Staggs: Well, thanks for the questions, Mark and Bill, and thanks for joining the call. I’m around today. The team is around today and tomorrow if you’d like to reach out and hope everyone has a good day. Bye-bye.
Operator: Thank you, everyone. This concludes today’s event. You may disconnect at this time, and have a wonderful day. Thank you for your participation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
